FierceBiotech19h
Intellia's CRISPR and Alnylam's RNAi data drops present contrasting visions for cardiomyopathy care
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.
BioSpace18h
Intellia’s CRISPR Gene Editor Shows Early Promise With Strong Biomarker Benefit in ATTR Amyloidosis
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...
Intellia Therapeutics Announces Promising CRISPR Therapy Results
Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...
STAT2d
Intellia says CRISPR therapy shows superior gain for cardiomyopathy patients
Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.
Business Insider1d
Intellia Therapeutics Receives Buy Rating: Promising NTLA-2001 Trial Results Highlight Competitive Advantage
Terence Flynn has given his Buy rating due to a combination of factors that highlight Intellia Therapeutics’ promising clinical data and competitive positioning in the market. The recent updates from ...
Intellia’s gene editing therapy shows early potential in rare heart condition
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
Investing6d
Intellia Therapeutics' SWOT analysis: gene editing stock's progress and potential
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biotechnology company specializing in CRISPR/Cas9 gene editing technology, has been making significant strides in its clinical development ...